What is Morphosys's official website?

Morphosys's website is morphosys.com

What is Morphosys's industry?

Morphosys's industry is Biotechnology Research

Who are Morphosys's top competitors?

Morphosys's top competitors are , , , , , ,

Morphosys company information, Employees & Contact Information

Explore related pages

Morphosys email format Morphosys management contacts

Related company profiles:

For additional information on our community guidelines, please visit https://www.novartis.com/corporate-social-media-community-management-guidelines

Employees: 325
Address: Semmelweisstr. 7, Planegg,bayern 82152,germany
Phone: +49 89 899270
Email: in****@****sys.com
Industry: Biotechnology Research
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)
Website: morphosys.com
Keywords: Cancer, Inflammation, Biologics, Antibodies, Biotechnology, Epigenetics.
HQ: Planegg, Bayern
Competitors: Medigene AG, CureVac, Eisbach Bio GmbH, Formycon AG, Novartis, BioNTech SE, PROTEROS biostructures GmbH, Immatics, Tubulis GmbH, Catalent.

Morphosys Questions

News

Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting - ACCESS Newswire

Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting ACCESS Newswire

MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer - ACCESS Newswire

MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer ACCESS Newswire

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting - Yahoo Finance

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting Yahoo Finance

Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease - BioPharma Dive

Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease BioPharma Dive

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Business Wire

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Business Wire

Novartis Initiates Voluntary Public Takeover of MorphoSys AG - Pharmaceutical Executive

Novartis Initiates Voluntary Public Takeover of MorphoSys AG Pharmaceutical Executive

Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years - Fierce Biotech

Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years Fierce Biotech

FDA Grants Fast Track Status to Tulmimetostat for Endometrial Cancer - OncLive

FDA Grants Fast Track Status to Tulmimetostat for Endometrial Cancer OncLive

New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition - statnews.com

New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition statnews.com

Novartis tender offer for MorphoSys AG commences - Novartis

Novartis tender offer for MorphoSys AG commences Novartis

Novartis to acquire cancer-focused MorphoSys for $2.9 billion - Reuters

Novartis to acquire cancer-focused MorphoSys for $2.9 billion Reuters

MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab - ACCESS Newswire

MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab ACCESS Newswire

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability - Yahoo Finance

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability Yahoo Finance

MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders - Business Wire

MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders Business Wire

MANIFEST-2 Study of Pelabresib Plus Ruxolitinib Completes Enrollment in Myelofibrosis - OncLive

MANIFEST-2 Study of Pelabresib Plus Ruxolitinib Completes Enrollment in Myelofibrosis OncLive

MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency - ACCESS Newswire

MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency ACCESS Newswire

MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis - Business Wire

MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis Business Wire

Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters - Yahoo Finance

Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters Yahoo Finance

Invitation to Year-End Results 2017 Conference Call - ACCESS Newswire

Invitation to Year-End Results 2017 Conference Call ACCESS Newswire

After Incyte's commercial buy, Novartis shells out €2.7B for cancer specialist MorphoSys - Fierce Biotech

After Incyte's commercial buy, Novartis shells out €2.7B for cancer specialist MorphoSys Fierce Biotech

Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab - Business Wire

Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab Business Wire

Novartis leads race to acquire Monjuvi maker MorphoSys: Reuters - Fierce Pharma

Novartis leads race to acquire Monjuvi maker MorphoSys: Reuters Fierce Pharma

Preclinical study of CD19 detection methods post tafasitamab treatment - Frontiers

Preclinical study of CD19 detection methods post tafasitamab treatment Frontiers

Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing - Fierce Biotech

Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing Fierce Biotech

Phase III B-MIND Study Passes Futility Analysis for Patients with DLBCL - CancerNetwork

Phase III B-MIND Study Passes Futility Analysis for Patients with DLBCL CancerNetwork

MorphoSys (MOR) Stock Price, News & Analysis - MarketBeat

MorphoSys (MOR) Stock Price, News & Analysis MarketBeat

New Strategies for Targeting CD38 in Multiple Myeloma Take Root - OncLive

New Strategies for Targeting CD38 in Multiple Myeloma Take Root OncLive

MorphoSys : to Present at Upcoming Investor Conferences - MarketScreener

MorphoSys : to Present at Upcoming Investor Conferences MarketScreener

MorphoSys Celebrates 25th Anniversary - ACCESS Newswire

MorphoSys Celebrates 25th Anniversary ACCESS Newswire

Is CD37-Targeted Therapy a Viable Alternative in the Treatment of Diffuse Large B-cell Lymphoma? Interviews with Two Key Opinion Leaders - European Medical Journal

Is CD37-Targeted Therapy a Viable Alternative in the Treatment of Diffuse Large B-cell Lymphoma? Interviews with Two Key Opinion Leaders European Medical Journal

Characterization and screening of IgG binding to the neonatal Fc receptor: mAbs: Vol 6, No 4 - Taylor & Francis Online

Characterization and screening of IgG binding to the neonatal Fc receptor: mAbs: Vol 6, No 4 Taylor & Francis Online

I-Mab Biopharma : and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma - MarketScreener

I-Mab Biopharma : and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma MarketScreener

Antibody Therapies for Patients With Diffuse Large B-cell Lymphoma: What Does the Future Hold? - European Medical Journal

Antibody Therapies for Patients With Diffuse Large B-cell Lymphoma: What Does the Future Hold? European Medical Journal

MorphoSys : CSO Marlies Sproll Takes Temporary Leave Markus Enzelberger to Serve as Interim CSO - MarketScreener

MorphoSys : CSO Marlies Sproll Takes Temporary Leave Markus Enzelberger to Serve as Interim CSO MarketScreener

Companies like Morphosys

Top Morphosys Employees

Tim Demuth, M.D., Ph.D.

Chief Research & Development Officer At Morphosys

N/a

View
Eric M. Jacobson Ph.D.

Regulatory Writer/Consultant/Scientist

Cincinnati, Ohio, United States, United States

View

3
synchrogenix.com, mssm.edu, gmail.com
Rakesh Dadhania

Clinical Research Professional, Biosimilar Development, Blend Of Working At Sponsor As Well As Cro In Early & Late Development, Start-Up

Greater Munich Metropolitan Area, Germany

View
Virginie Pontlevoy

Vice-President, General Counsel

Munich, Bavaria, Germany, Germany

View

1
morphosys.com

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Morphosys company information, Employees & Contact Information

Explore related pages

Company Details

Morphosys Questions

What is Morphosys's helpline number?

What is Morphosys's official website?

What is Morphosys's LinkedIn profile?

How many employees are working in Morphosys right now?

What is Morphosys's industry?

What are Morphosys's top competitors?

What is Morphosys's support email address?

What are Morphosys's categories?

News

Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting - ACCESS Newswire

MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer - ACCESS Newswire

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting - Yahoo Finance

Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease - BioPharma Dive

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Business Wire

Novartis Initiates Voluntary Public Takeover of MorphoSys AG - Pharmaceutical Executive

Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years - Fierce Biotech

FDA Grants Fast Track Status to Tulmimetostat for Endometrial Cancer - OncLive

New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition - statnews.com

Novartis tender offer for MorphoSys AG commences - Novartis

Novartis to acquire cancer-focused MorphoSys for $2.9 billion - Reuters

MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab - ACCESS Newswire

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability - Yahoo Finance

MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders - Business Wire

MANIFEST-2 Study of Pelabresib Plus Ruxolitinib Completes Enrollment in Myelofibrosis - OncLive

MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency - ACCESS Newswire

MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis - Business Wire

Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters - Yahoo Finance

Invitation to Year-End Results 2017 Conference Call - ACCESS Newswire

After Incyte's commercial buy, Novartis shells out €2.7B for cancer specialist MorphoSys - Fierce Biotech

Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab - Business Wire

Novartis leads race to acquire Monjuvi maker MorphoSys: Reuters - Fierce Pharma

Preclinical study of CD19 detection methods post tafasitamab treatment - Frontiers

Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing - Fierce Biotech

Phase III B-MIND Study Passes Futility Analysis for Patients with DLBCL - CancerNetwork

MorphoSys (MOR) Stock Price, News & Analysis - MarketBeat

New Strategies for Targeting CD38 in Multiple Myeloma Take Root - OncLive

MorphoSys : to Present at Upcoming Investor Conferences - MarketScreener

MorphoSys Celebrates 25th Anniversary - ACCESS Newswire

Is CD37-Targeted Therapy a Viable Alternative in the Treatment of Diffuse Large B-cell Lymphoma? Interviews with Two Key Opinion Leaders - European Medical Journal

Characterization and screening of IgG binding to the neonatal Fc receptor: mAbs: Vol 6, No 4 - Taylor & Francis Online

I-Mab Biopharma : and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma - MarketScreener

Antibody Therapies for Patients With Diffuse Large B-cell Lymphoma: What Does the Future Hold? - European Medical Journal

MorphoSys : CSO Marlies Sproll Takes Temporary Leave Markus Enzelberger to Serve as Interim CSO - MarketScreener

Companies like Morphosys

Catalent

Medigene Ag

Curevac

Tubulis Gmbh

Proteros Biostructur...

Eisbach Bio Gmbh

Biontech Se

Novartis

Formycon Ag

Immatics

Top Morphosys Employees

Tim Demuth, M.D., Ph.D.

Chief Research & Development Officer At Morphosys

Eric M. Jacobson Ph.D.

Regulatory Writer/Consultant/Scientist

Rakesh Dadhania

Clinical Research Professional, Biosimilar Development, Blend Of Working At Sponsor As Well As Cro In Early & Late Development, Start-Up

Virginie Pontlevoy

Vice-President, General Counsel

Free Chrome Extension

Aero Online

Select data to include:

How It Works

Get a Free Account

Search the #1 Contact Database

Use our AI-Powered Email Finder

Have a look at Aeroleads Data